Day: December 9, 2025

AMF doctrine shift follows UK and Nordic moves; CoinShares leads the European market with a 32% AUM share 9 December 2025 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF) — a leading global asset manager specialising in digital assets, which has announced a merger with Vine Hill Capital Investment Corp (Nasdaq: VCIC), welcomes France’s AMF decision to open retail access to regulated crypto ETNs. Europe’s crypto exchange-traded product market is entering a new growth phase as regulators and major financial institutions across the continent move to expand retail investor access. Key developments:France: The AMF adapted its doctrine to permit retail marketing of crypto-indexed ETNs, removing warning-label requirements for...

PARAMUS, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) — Alexander’s, Inc. (NYSE: ALX) today announced that it has completed a $175 million refinancing of its 615,000 square foot Rego Park II shopping center located in Queens, New York. The interest-only loan is at SOFR plus 2.00%, currently 5.82%, and matures in December 2030. Alexander’s paid down by $23.5 million the prior $198.5 million loan that bore interest at SOFR plus 1.45% and was scheduled to mature on December 12, 2025. Alexander’s, Inc. is a real estate investment trust that has five properties in New York City. CONTACT:GARY HANSEN(201) 587-8541 Certain statements contained herein constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking...

Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right (“CVR”). Each CVR entitles its holder to an additional payment of 6 USD per share in cash (or aggregated value of 0.5 billion USD) upon US regulatory approval of Akero’s lead candidate EFX for the treatment of compensated cirrhosis due to MASH. At the completion of the transaction, Akero became a wholly owned subsidiary of Novo Nordisk. The common...

Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) — Latin Metals Inc. (“Latin Metals” or the “Company”) – (TSXV: LMS, OTCQB: LMSQF) is pleased to announce that, further to the Company’s news release dated October 24, 2025, the Company has entered into an arrangement agreement dated December 8, 2025 (the “Arrangement Agreement“) with Latin Explore Inc. (“Latin Explore“), a wholly-owned non-arm’s length subsidiary of the Company, pursuant to which the parties intend to complete a spin-out transaction (the “Spin-Out“) of the Company’s Para and Auquis...

Tucson Water Enters New Era of Innovation with Cellular-Based AMI LIBERTY LAKE, Wash., Dec. 09, 2025 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, is working with the City of Tucson | Tucson Water in Arizona to enhance water conservation efforts with Itron’s Advanced Metering Infrastructure (AMI) Essentials for water. AMI Essentials for water is Itron’s new standard bundled AMI solution, tailored to better serve small- to medium-sized water utilities in the United States. In geographical areas where water preservation is at the forefront of sound water resource management, effective conservation requires greater visibility into the water distribution network. This deployment marks a new era of innovation for the city as it lays the technological...

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates  The K-Ras G12V mutation is the oncogenic driver for 1/3 of all pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer Significant unmet need in pancreatic cancer where median overall survival (OS) is 1.4 years1 TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced key preclinical data demonstrating the therapeutic potential of its novel ADC targeting Trop2, AKTX-101, in pancreatic cancer driven by K-Ras mutations, one of the deadliest and most...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1 Teva is committed to advancing this innovative treatment option and further build on its differentiated LAI franchisePARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-‘749) for the treatment...